Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

Benzinga Newsdesk www.benzinga.com Positive 60.7%

Neg 0% Neu 0% Pos 60.7%

Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.